Chief Executive Officer
Sean McCarthy has more than 18 years of experience in the biotechnology industry, including business development, venture capital, program management and research management. Prior to joining CytomX in January 2011, he was a transactional partner at Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies and new company formation. Prior to Pappas Ventures, Dr. McCarthy was the vice president of business development at SGX Pharmaceuticals Inc., where he spearheaded a wide range of strategic partnerships with major pharmaceutical companies, including a $515 million oncology alliance with Novartis, and led a strategic re-orientation that resulted in the successful initial public offering of the company in 2006. Prior to SGX, Dr. McCarthy was associate director of program management at Millennium Pharmaceuticals, where he managed therapeutic protein programs and a research team that invented novel genomic techniques for the identification of novel biologics. Dr. McCarthy is the author of 17 peer-reviewed scientific publications and a named inventor on six issued patents and 23 filed patent applications.
Dr. McCarthy received his B.Sc. in biochemistry and pharmacology at King's College, University of London; his M.B.A. from the Rady School of Management at UC San Diego; and a D. Phil. in cancer biology from St. John's College, University of Oxford.
Chief Scientific Officer
Henry Lowman joined CytomX in September 2010 as vice president of research and has since been promoted to chief scientific officer. Most recently, Dr. Lowman was the director of protein sciences at NGM Biopharmaceuticals. Prior to that, Dr. Lowman served a 20-year tenure at Genentech, Inc., where he focused on the research and development of protein and antibody therapeutics. He began his career as a National Institutes of Health Postdoctoral Fellow at Genentech, and then moved on to roles as scientist and senior scientist in the protein engineering department, before leading Genentech's antibody engineering department as associate director and then director. His career interests include structure-based protein design, structure-function analysis and molecular diversity techniques, which he has applied in therapeutic development projects such as human growth hormone and IGF-1, as well as to therapeutic antibodies directed against IgE, VEGF, and CD20. Dr. Lowman is an author on more than 60 scientific publications, inventor on more than 60 issued patents and an editorial board member for the antibody journal mAbs.
Dr. Lowman earned his B.A. at Johns Hopkins University and Ph.D. at Purdue University, with both degrees in chemistry.
Chief Medical Officer
Krishna Polu, a nephrologist, serves as chief medical officer and is responsible for the translational and clinical strategy and execution for the Cytomx Probody™ programs. Throughout his career, he has had significant experience with drug development and regulatory interactions and approvals for biologics. Previously, Dr. Polu served as vice president and head of clinical development for Affymax. Prior to joining Affymax, Dr. Polu served as executive director, global development and in various clinical development leadership roles at Amgen, where he was responsible for late-stage clinical programs in nephrology, diabetes and heart failure. Before joining Amgen, Dr. Polu was a clinical and research fellow at Harvard Medical School in the renal division at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Polu has co-authored nine peer-reviewed publications and several book chapters.
Dr. Polu earned a B.A. in human biology from Stanford University and an M.D. from University of Texas Health Science Center, San Antonio. He completed his residency training in internal medicine at the University of Colorado.
Fletcher Payne has more than 20 years of experience helping life-science companies achieve their business goals. In his role as CFO, Mr. Payne focuses on raising capital, developing strategic financial plans, managing business growth, implementing corporate partnerships, and managing business performance. His life-science experience includes successful start-ups, initial public offerings, mergers, spin-outs and working with R&D teams whose efforts have led to four products receiving approval by the U.S. Food and Drug Administration. During his career, he has worked with Pathwork Diagnostics, Plexxikon, Rinat Neuroscience, Dynavax Technologies, Cell Genesys, Abgenix, Sun Micro Systems and IBM.
Mr. Payne is a graduate of the Walter A. Haas School of Business at University of California, Berkeley.
Vice President, Business Development and Alliance Management
Debanjan Ray has more than 10 years of experience in the biotechnology industry, including strategic consulting, venture capital and business development. Prior to joining CytomX in August of 2011, Mr. Ray was the vice president of business development at Itero Biopharmaceuticals, where he helped drive several collaborations including the company's partnership on its lead product with Watson Pharmaceuticals. Prior to Itero, Mr. Ray was an associate director of business development at Portola Pharmaceuticals. Previously, Mr. Ray was an associate in the life sciences venture practice at J.P. Morgan Partners and a business analyst in the healthcare practice at McKinsey & Company.
Mr. Ray holds a dual B.S. in chemical engineering and biology from the Massachusetts Institute of Technology and an M.B.A. from The Wharton School, University of Pennsylvania.